Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Nordic Nanovector ASA: Share capital increase registered

Date: 02.02.2017        Press Release no: 4/2017

Oslo, Norway, 2 February 2017

Reference is made to the stock exchange notice published by Nordic
Nanovector ASA (the "Company") (OSE: NANO) on 24 January 2017 where
the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with
the exercise options pursuant to the Company's employee share option

The share capital increase has been duly registered in the Norwegian
Register of Business Enterprises. Following such registration the
Company's share capital is NOK 9,806,228.60 divided into 49,031,143
shares, each with a nominal value of NOK 0.20.

For further information, please contact:

Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76

About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab
(previously referred to as HH1), conjugated to a low intensity
radionuclide (lutetium-177). The preliminary data has shown promising
efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at
developing Betalutin® for the treatment of major types of NHL with
first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline
to treat multiple selected cancer indications.

Further information about the Company can be found at

This information is subject to duty of disclosure pursuant to Section
3.2 of the Continuing obligations for listed companies.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.